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Cardiac magnetic resonance imaging (CMR) has long
been recognized as an accurate and reliable means of
evaluating cardiac anatomy and ventricular function.
Considerable progress has been made in the field of
CMR, providing accurate evaluation of myocardial
ischemia and infarction [1–3]. Contrast-enhanced
CMR can be used to visualize the transmural extent
of myocardial infarction with high spatial resolution
[4–6]. Infarcted myocardium appears hyperenhanced
compared with normal myocardium when imaged by a
late enhancement MRI technique with the use of
T1-weighted sequence after injection of gadolinium
chelates. Late gadolinium-enhanced CMR can clearly
delineate subendocardial infarction and the transmural
extent of delayed enhancement potentially predicts
functional outcome after revascularization in acute
myocardial infarction and chronic ischemic heart
disease [7]. Stress first-pass contrast-enhanced myo-
cardial perfusion CMR can be used to detect
subendocardial ischemia and recent studies have
demonstrated the high diagnostic accuracy of stress
myocardial perfusion CMR for detecting significant
coronary artery disease [8–10]. Magnetic resonance
angiography (MRA) was recently introduced as a
method that can provide visualization of all three major
coronary arteries, coronary bypasses, and the aorta
within a single three-dimensional acquisition [11, 12].
CMR has become the first choice imaging modality in
complex congenital heart disease [13–16] and imaging
great vessels [17, 18]. In recent years, late gadolinium
enhancement CMR has also been used to visualize
myocardial interstitial abnormalities. Previous studies
have clearly shown late enhancement patterns in
patients with different forms of cardiomyopathies,
amyloidosis, myocarditis, and storage diseases
[19–22]. Silva et al. [20] showed that late gadolinium
enhancement can be demonstrated in cardiomyopathy
patients, with a mean signal intensity of 390 ± 220%
compared with normal regions. The affected areas
included papillary muscles (sarcoid), the mid-myocar-
dium (Anderson-Fabry disease, glycogen storage
disease, myocarditis, Becker, and Duchenne muscular
dystrophy) and the global subendocardium (systemic
sclerosis, Loeffler’s endocarditis, amyloid, and Churg-
Strauss). Focal myocardial late gadolinium enhance-
ment is found in the specific cardiomyopathies, and the
pattern is distinct from that seen in myocardial
infarction, recent studies have demonstrated right
ventricular late gadolinium enhancement in patients
with congenital heart disease and right ventricular
loading conditions [14, 23]. Myocardial preservation is
likely a multifactorial process that may affect the right
and left ventricles differently [24–28].
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In an article in the present issue of the International
Journal of Cardiovascular Imaging, Puchalski et al.
[29] studied late gadolinium enhancement with CMR
in 74 patients with Duchenne muscular dystrophy.
Duchenne’s disease is an X-linked recessive inherited
disorder with an annual incidence of 1/3,000 live male
births. Pre-clinical cardiac involvement has been
found in 25% of patients under 6 years old increasing
to 60% between the ages of 6 and 10 years and then
declining in incidence with age. Clinically apparent
cardiomyopathy is first evident after 10 years of age
and increases in incidence with age, being present in
all patients over 18 years of age. Unlike in connective
tissue disease such as Marfan [30], progressive
cardiomyopathy is a common cause of death in
Duchenne muscular dystrophy, presumably secondary
to fibrosis of the myocardium. The posterobasal and
left lateral free wall of the left ventricle are initial sites
of myocardial fibrosis pathologically. The purpose of
the present study [29] was to assess whether late
gadolinium enhancement could identify fibrosis in
selective areas of the myocardium. In addition, the
relationship between the presence and extent of
fibrosis and left ventricular function was established.
Of the 74 patients, 24 patients (32%) had late
gadolinium enhancement involving the posterobasal
region of the left ventricle in a subepicardial distri-
bution. Those patients with more involvement had
spread to the inferior and left lateral free wall with
progressive transmural fibrous replacement. There
was relative sparing of the interventricular septum and
right ventricle. As a result, late enhancement was able
to detect fibrosis in selective regions of myocardium
in patients with Duchenne’s disease. The presence of
late gadolinium enhancement was associated with
diminished cardiac function. Recently, Silva et al.
[31] showed in 10 patients with muscular dystrophy
that CMR could identify myocardial fibrosis and may
be useful for detecting the early stages of cardiomy-
opathy in myocardial dystrophy. Myocardial fibrosis
(midwall and/or subepicardial) was observed in 7 out
of 10 patients, and the lateral wall was the most
commonly involved segment. There was moderate
correlation between segmental myocardial fibrosis
and left ventricular dysfunction. Another recent CMR
study in 32 young patients with Duchenne muscular
dystrophy by Mertens et al. [32] showed a global
normal systolic function, but reductions in systolic
deformation parameters as well as reduced early
diastolic myocardial velocities in the anterolateral and
inferolateral left ventricular walls. The prognostic
significance of these findings warrants further longi-
tudinal follow-up studies to determine whether late
gadolinium enhancement precedes a decrease in
cardiac function, and whether early pharmaceutical
interventions are useful in preventing progression of
Duchenne muscular dystrophy. Recent clinical studies
with corticosteriods have already shown promising
results by their potential to retard development of left
ventricular dysfunction [33, 34]. Mavrogeni et al. [33]
showed that Duchenne patients on deflazacort are
characterized by better preservation of the CMR T2
relaxation time of the myocardium and an improved
left ventricular systolic function. Markham et al. [34]
demonstrated that treatment of Duchenne patients
with steroids was protective against left ventricular
dysfunction. This indicates that steroid treatment,
when started prior to ventricular dysfunction, retarded
the anticipated development of ventricular dysfunc-
tion in Duchenne patients. Larger functional studies—
preferably with CMR—are still needed to establish
the true value of corticosteroids in delaying the
development of cardiomyopathy in patients with
Duchenne muscular dystrophy.
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